1 Objective: Genome-wide association studies (GWAS) have successfully identified 145 loci 2 implicated in schizophrenia (SCZ). However, the underlying mechanisms remain largely 3 unknown. 4
Introduction
3 Schizophrenia (SCZ) is a debilitating, highly heritable and polygenic psychiatric condition 4 affecting roughly 1% of the population. Recent GWAS have successfully identified 145 risk loci by 5 meta-analysis of samples through the UK CLOZUK and the Psychiatric Genomics Consortium 6 (PGC2) and compared allele frequency differences between SCZ patients and normal controls 7 (1) . While these findings have identified regions in the genome harboring SCZ genes, almost all 8 of the regions include multiple genes that are located within the same recombination hotspot 9 intervals, making it challenging to identify causal genes. 10 One essential approach to determining the function of the identified SNPs is to combine GWASs 11 with gene expression in post-mortem human brains. Recently, several studies have applied 12 these strategies to the 108 loci identified by the PGC in 2014 (2). Using genotyped RNA 13 sequencing (RNA-seq) data generated by the CommonMind Consortium from postmortem 14 dorsolateral prefrontal cortex (DLPFC), splicing Quantitative Trait Loci (QTL) were found to be 15 significantly enriched in SCZ risk loci (3) . The enrichment of SCZ loci was also observed in 16 another independent study of postmortem brain DLPFC samples (4) , suggesting that combining 17 these analytical techniques provides important insights into the mechanisms underlying SCZ. 18 Studies integrating expression QTL (eQTL) and GWAS data have almost exclusively used 19 quantified expression across multiple transcript features, including annotated genes as well as 20 annotation-guided transcripts. Notably, junction calls from short RNA-seq reads are considerably 21 more reliable than assembled transcripts (5) . However, only a limited number of studies 22 employed exon-exon splice junctions to identify splicing transcripts that contribute to the 23 underlying phenotypes (4) . Recently, skipping of exon 2 and exon 3 of AS3MT was identified to 1 contribute to SCZ risk using large postmortem brain cohorts (6) . Using the same specimens, we 2 also successfully identified risk allele of SCZ SNPs are strongly associated with splicing junctions 3 between exon 8 and exon 10 of SNX19 (7) . 4
Here, we leveraged genotype and brain expression data provided by the Genotype-Tissue 5 Expression (GTEx) project to elucidate the functional properties and potential roles of eQTL and 6 splicing expression features in the etiology of SCZ. Integrating the GTEx brain eQTLs with the 7 most recent SCZ GWAS data (CLOZUK +PGC2) (1), we evaluated specific effects of the identified 8 SCZ risk variants on gene expression features in combination with epigenetics data, and 9 examined how genes of expression features affect genetic networks. Our co-localization 10 analyses identify specific targets implicated in SCZ and highlight new biological insights for 11 further investigation in future studies. 12
Materials and methods

13
RNA-seq of postmortem brain 14 A total of 1,497 human brain samples across 13 brain regions were used in this study (Table 1) . 15
All of the postmortem brain samples were collected by the GTEx consortium. The sample 16 procurement has been described previously (8) . Raw gene and exon-exon junction reads counts 17 were retrieved from GTEx portal (https://gtexportal.org/home/datasets). Gene lengths were 18 calculated using GENCODE v19 annotations (9) . We converted gene counts to RPKM (Reads per  19 Kilobase per Million mapped reads) values using the total number of aligned reads across the 22 20 autosomal chromosomes. Considering a median depth of 84 million reads in the sequencing 21 (Table 1) , we converted junction counts to RP80M values (reads per 80 million mapped) using 22 the total number of aligned reads across the autosomal chromosomes, which can be interpreted 1 as the number of reads supporting the junction in an average library size (4). 2 Genotyping data 3 Whole-genome sequencing (WGS) datasets were retrieved from dbGap upon authentication by 4 the GTEx Consortium (Accession: phs000424.v7.p2). GTEx called all variants using GATK 5 HaplotypeCaller (8) . We extracted a total of 42,585,769 genomic variants which were then 6 filtered step-by-step by using PLINK 1.9 (10) if they: 1) had a genotype missing rate >10% 7 (272,734 variants); 2) had minor allele frequencies < 1% (31,110,395 variants); and 3) deviated 8 from Hardy-Weinberg equilibrium (p-value < 1E−5, 791,170 variants). Finally, we retained 9 10,411,470 variants for further analysis. 10 cis-acting eQTL analysis 11 cis-eQTL association was implemented separately by feature type (gene and junction) using 12
Matrix eQTL R package (11) with the additive linear model, treating log2-transformed expression 13 levels of each measurement (RPKM and RP80M) as the outcome. Low expression features 14 (average counts < 0) were excluded before eQTL analysis. To control for potential confounding 15 factors, we adjust for ancestry (first three principle components (PCs) from the genotype data) 16 (12) , sex, and the first K PCs of the normalized expression features, where K was calculated 17 separately by feature type using the sva Bioconductor package (gene: 13 PCs, junction: 13 PCs). 18
False discovery rate (FDR) was assessed using the Benjamini-Hochberg algorithm (BH) across all 19 cis-eQTL tests within each chromosome. We considered all variant-gene pairs (eGene) and 20 variant-junction pairs (eJunction) when the distance between features and SNP is less than 1MB. 21 1 In order to assess the probability that molecular traits as estimated by cis-eQTLs and 2 physiological traits as estimated by GWAS share the same causal variant, we co-localized 3 8,171,061 SCZ GWAS summary statistics (1) with our eGene and eJunction results. We used SMR 4 and HEIDI tests for the co-localization analysis (13) . We used the default parameters and 5 performed for the genes and junctions. SNPs with LD r-squared between top-SNP > 0.90 or < 6 0.05 were excluded as well as one of each pair of the remaining SNPs with LD r-squared > 0.90. 7
Co-localization of GWAS and eQTL associations
In addition, we conducted mappings of eGene and eJunction with SCZ GWAS separately. In the 8 mapping process, any variants without either eQTL or GWAS association statistics were 9 excluded. 10 transcription factors (TF), ENCODE TF binding data was downloaded (15) . Then, we used 17
SNP annotation
BEDTools intersect (16) to match SNPs to ChIP-seq peaks. Brain histone ChIP-seq data were 18 obtained from the ENCODE portal (https://www.encodeproject.org/). In addition, histone 19 acetylation QTLs data (H3K9Ac ChIP-seq) generated from DLPFC of 433 individuals and DNA 20 methylation QTLs data generated from 468 individuals were obtained from Brain xQTL Server 21 (17) . 22
Functional enrichment 1 We used three tools (WebGestalt (18) , DAVID (19) , and gProfiler (20) ) for overrepresentation 2 enrichment analysis which help us identify biological pathways that are significantly enriched in 3 a gene list. The transcript features were mapped to Entrez Gene IDs and subsequently to KEGG 4 pathway. Gene ontologies (GO) biological process and GO molecular function (21) were also 5 calculated. FDR (BH) and fold enrichment were imputed. FDR < 0.001 was used as threshold. 6
Results
7
Transcriptome-wide association study 8 Alterations in the brain have been demonstrated to underlie cognitive deficits associated with 9 SCZ, including impairments in working memory and cognitive flexibility (22) . To better 10 understand the genetic interactions between expression features and genomic variations, we 11 analyzed RNA-seq data of 13 brain regions from 1,497 postmortem brains in combination with 12 WGS data. We comprehensively identify cis-QTLs and expression features (gene and exon-exon 13 splicing junctions) in the human brain with quality-controlled SNP genotyping data from the 14 same individuals using Matrix eQTL (11) in a genome-wide manner (see Methods for details). To 15 conservatively define eGene and eJunction SNPs, we applied BH procedure for multiple testing 16 implemented in Matrix eQTL to the p-values. To evaluate the extent of overlap between eQTL 17 and GWAS signatures in SCZ and to identify putative causative genes from GWAS associations, 18
we then performed co-localization analyses by SMR methods using default parameters. We also 19 performed mapping for an in-depth investigation. After performing these procedures, we 20 identified a total of 55 genes (SMR) and 89 genes (mapping) in eGene (Table S1 and Table S2 ) 21 and 186 junctions within 78 genes (SMR) and 343 junctions within 133 genes in eJunction 22 (mapping) ( Table S3 and table S4) As expected, most of the signals are from the major histocompatibility complex (MHC) region: 3 32/55 (SMR) and 51/89 (mapping) genes within eGene (Table S1 and Figure 1A ), and 41/78 and 4 74/133 (mapping) genes within eJunction (Table S1-4). The MHC is located in chromosome 6p21 5 and contains crucial regulators of the immune response. The MHC is the most gene dense and 6 most polymorphic region of the human genome (23) . Complement component 4 (C4) structural 7 variation was recently demonstrated to be related to the expression of C4A and C4B in 8 postmortem brain (24) . In the current study, while C4A was detected in three brain regions in 9 gene level by both SMR and mapping, C4A appeared across 10 brain regions in junction level by 10 both SMR and mapping ( Figure 1B and 1C, and Figure S3 , Table S3 and Table S4 ). AS3MT was 11 also replicated across several brain regions (Table S1-S4). 12 13 Alternative pre-mRNA splicing is a regulated process that results in a single gene coding for 14 multiple proteins by including or excluding particular exons of a gene. This generates spliced 15 mRNAs that direct the synthesis of a diverse set of proteins with varied biological functions. To 16 illuminate our understanding of SCZ risk in splicing junction level, we systematically evaluated 17 the exon-exon junctions in the human brain. We found eight splicing junctions located within 18 In prior work, we have systematically characterized splice junctions between exon 8 and exon 10 1 in SNX19 (7) . 2 3 To determine how SCZ GWAS relates to feature expression, we next analyzed the trends of the 4 associations. While SCZ risk allele is associated with down regulation of APOPT1 junction 5
Determination of splicing junctions
Effects of Schizophrenia genetic risk on junctions
Exon_3.4, all other risk alleles are associated with up regulation of junctions ( Figure S4 ). 6
Interestingly, SCZ risk allele is associate with up regulation of APOPT1 junction Exon_2.4 ( Figure  7 3). Opposing effects of SCZ risk allele on APOPT1 Exon_3.4 and the other two junctions indicate 8 their diverse functions. These robust effects are reproduced in the DLPFC and many other brain 9
regions (Table 1 ). Based on the genomic recombination rate, the GWAS-eQTL loci are in a 10 linkage block where recombination is not estimated to occur. In addition, a cluster of SNPs are in 11 high LD with top schizophrenia GWAS-eQTL SNPs: ARL6IP4 rs1790121, APOPT1 rs10431750 and 12 CYP2D6 rs133377 ( Figure S5 ). 13
Strikingly, we found CYP2D6 to be the top gene to be determined in both eGene and ejunction 14 across the 13 brain regions using both SMR and mapping (Figure 1 , Figure S1 -S3, Table S1-S4). 15
Therefore, we further investigated the CYP2D6 region. While multiple junctions were 16 determined to be significant at the junction level across the 13 brain regions, we also found 17
Exon_2.4, Exon_3.4, and Exon_7.8 to be significantly associated with SCZ risk SNPs ( Figure 4A Table S5 ). Interestingly, splicing occurred between exon 2 and exon 4 which 19 resulted in maintaining or skipping exon 3. Exon_78 was included in all CYP2D6 transcripts which 20 represents gene level (Figure 2) . 21
Functional characterization of eJunction SNPs in SCZ 1
Determining the underlying causal variants of complex disorders can be challenging because of 2 the complex linkage disequilibrium patterns between SNPs. We next attempted to functionally 3 characterize eQTL SNPs by classifying the 255 SNPs in SCZ GWAS eJunction according to the 4 definition in ANNOVAR (14) . As expected, most of the SNPs are non-exonic which accounts for 5 85.25% in SCZ GWAS eGene and 87.09% in SCZ GWAS eJunction ( Figure S9 and Table S5 ). There 6 are a total of seven exonic single nucleotide variant (SNV), four of which are non-synonymous. 7
Only one SNV was found in our target genes, which is, rs16947, located within exon 6 of CYP2D6 8 gene (NM_000106) ( Figure 2 and Table S5 ). Our CYP2D6 regional (2MB, about 5,000 SNPs) LD 9 analysis showed that SNPs in high LD with rs16947 are strongly associated with the abundance 10 of splicing junctions (Exon_34 and Exon_24) in DLPFC and other brain regions (Table S5 ). 11
Enhancers have emerged as key cis-regulatory elements that play important regulatory roles in 12 gene transcription, and they often reside distally from their target of regulation (25) . Using 13 ENCODE chromatin activation states from brain, we found that three SCZ splicing QTLs 14 (rs133375, rs133377 and rs4822088) are located within active transcription start sites (TSS) 15 ( Figure 4D ). Of the three SCZ splicing SNPs, rs133377 showed to be intercrossed with active 16 transcription state across all the brains (Table S6 ). Three histone marks on H3K27ac, H3K4me3, 17
and H3K9ac have been established to be associated with active transcription (26, 27) . As 18 expected, the three SNPs we identified are located within the chromatin modification peaks 19 ( Figure 4D ). Note that the three SNPs are in high LD with rs16947 (r 2 = 0.9539) ( Figure S10 and 20 Table S5 ). In addition, we analyzed another independent histone acetylation data and found 21 rs133377 is significantly associated with a histone acetylation site, peak16933 in a 2 MB sliding 22 window (chr22:42465478, p-value = 3.78E-8) ( Figure S11 and Table S7 ). DNA methylation plays 23 important roles in epigenetically regulating gene expression in the brain. Using DNA methylation 24 data of postmortem DLPFC brain from 468 individuals (17), we found 27 significant SNP-CpG 1 pairs scattered around CYP2D6 (Table S7) , implying they function together to regulate gene 2 transcription. 3 4 To further verify our systematic genomics results and gain mechanistic insight, we next took an 5 unbiased data-driven approach and performed a comprehensive gene-set pathway enrichment 6 analysis to explore the potential functional implications of the genome-wide significant genes 7 overlapped in junction level and gene level using WebGestalt, DAVID and gProfiler across the 13 8 brain regions. An average of 822 genes were determined and used for the enrichment analysis, 9
Enrichment analysis of eJunction
and more than 300 pathways were imputed by the three tools. Two top pathways that include 10 CYP2D6 are associated with metabolism of xenobiotics by cytochrome P450 (hsa00980) and 11 drug metabolism (hsa00982) and were consistently identified by each of the three tools across 12 the 13 brain regions ( Figure 4A , 4B, 4C, Figure S12 -S14, and Table S8 -S10). When we took an in-13 depth examination of the KEGG hsa00982 pathway, we found that CYP2D6, together with 14 several other determined genes, were associated with the metabolic process of psychiatric 15 drugs: tamoxifen, codeine and morphine, and citalopram ( Figure 4D and Figure S12-S14). 16 Similarly, GO biological process analyses showed CYP2D6 and related genes play a role in steroid 17 metabolic process in DLPFC and other brain regions (GO:0008202) (Table S11 ). GO molecular 18 function analyses showed CYP2D6 and 13 related genes involved in drug binding (GO:0008144) 19 in DLPFC and other brain regions (Table S12 ). 20
Discussion
21
In this study, we analyzed a large-scale transcriptome derived from 1,497 human postmortem 22 brain samples in combination with WGS data. SCZ is a complex genetic disorder and over a 23 hundred loci have been identified. However, it remains unclear how genetics affect the 1 abundance of expression features. We identified expression features and potential effective 2 splicing transcripts underlying SCZ susceptibility using the most recent GTEx brain RNA-seq data 3 (released on June 30, 2017) (8) and 2018 SCZ GWAS summary statistics (1) . We identify CYP2D6 4 to be an important candidate gene through several unbiased strategies: 1) by comparing gene 5 overlapping using SMR and mapping in gene and junction level across 13 brain regions; and 2) 6 through hypothesis-free over-representation enrichment analysis of eJunction genes. 7
Furthermore, by analyzing multiple sources of ChIP-seq data generated from postmortem 8 brains, we identify causal SNPs associated with CYP2D6. 9
Our principal findings include four major observations. First, we have identified a total of 171 10 genes across 13 brain regions for which genetic variation for expression co-localize with genetic 11 variation for SCZ risk. Some differences in results are expected using alternative co-localization 12 methods and references. Using 206 postmortem brain DLPFC samples from normal individuals, 13
Takata et al evaluated SCZ risk loci that are involved in splicing events based on assembled 14 transcripts (3). In the current study, we replicated reported genes, for example, SNX19, ARL6IP4, 15 APOPT1 (3), C4A and C4B (24), and discovered new genes such as CYP2D6. 16
Second, we identified a list of exon-exon junctions that tag genetic transcripts. In prior work, 17 most analyses focus almost exclusively on the marginal eQTL signal which typically represents 18 the primary, or most significant, eQTL signal, rather than dissecting this signal into multiple 19 independent features for each gene. While predicted transcripts are more likely to be used as a 20 reference, we used exon-exon junctions to tag specific transcripts which considerably increases 21 specificity. Our eJunction analyses identify eight splicing junctions that are located in four genes. 22
Our recent study has systematically evaluated SNX19 Exon_8.10 transcripts and their potential 23 susceptibility to SCZ (7) . APOPT1 was demonstrated to be located in mitochondria matrix, and 1 involved in possessing an N-terminal mitochondrial targeting signal (28) . ARL6IP4 play a 2 functional role in pre-mRNA splicing (29, 30) . However, the mechanisms of APOPT1 and ARL6IP4 3 are still largely unknown. 4
Third, we illustrated an underlying mechanism for SCZ risk. There is accumulating evidence that 5 Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of clinically used drugs (31) . A 6 clinical study reported that CYP2D6 plays an important role in controlling the state of 7 aripiprazole in the plasma which has been established as a form of treatment for SCZ (32) . 8 CYP2D6 has also been reported to have significant effects on psychotic symptoms (33) and 9 cognitive performance (34) of SCZ patients following risperidone treatment. Our data-driven 10 enrichment analysis identified CYP2D6 as a significant eGene and eJunction gene and as a key 11 component of the drug metabolism pathway (specifically related to codeine, citalopram, 12 morphine and tamoxifen). CYP2D6/codeine has been highlighted as an antidepressant 13 gene/drug pair in clinical therapy by Clinical Pharmacogenetics Implementation Consortium (35) . 14 Codeine is bioactivated into morphine by CYP2D6 to exert its analgesic effect. Morphine, a 15 strong opioid agonist, acts directly on the central nervous system and has been strongly 16 implicated in addiction and SCZ pathophysiology (36) . Citalopram is a selective serotonin 17 reuptake inhibitor used to treat major depression disorders (37) . Tamoxifen is well-known as an 18 estrogen receptor modulator commonly used to treat breast cancer. In addition, we observed 19 CYP2D6 to be involved in the metabolism of neuroactive steroids which are present in human 20 post-mortem brain tissue. In fact, concentrations of neuroactive steroids are known to be 21 altered in subjects with SCZ and bipolar disorder (38) . Overall, these findings highlight CYP2D6 as 22
an important candidate for further biological investigation. For example, it would be interesting 23 to investigate how CYP2D6 interacts with the top identified SCZ risk genes and contributes to 24 SCZ risk. It would also be interesting to determine how the diverse CYP2D6 transcripts 1 differentially affect the metabolism of psychiatric drugs. 2 Finally, by characterizing the properties of the detected eJunction SNPs, we found one non-3 synonymous SNV, rs16947, located within CYP2D6 exon 6, to be associated with abundance of 4 splicing junctions related to its exon 3 skipping. This leads to an in-frame deletion that shortens 5 the translated protein by 51 amino acids. This risk allele of the SNV could result in an amino acid 6 substitution that has been shown to reduce enzyme activity after recombinant cDNA 7 transfection (39, 40) . On the other hand, we found three SNPs, which are in strong LD with 8 rs16947, to be located within active chromatin modification regions in the brain, indicating that 9 they are actively involved in direct regulation of CYP2D6 gene transcription (26, 27) . Thus, taken 10 together, it is conceivable these alterations (changes in protein structure and/or chromatin 11 modifications) affect the transcriptional activity of CYP2D6, leading to downstream changes in 12 gene expression, which could further alter enzyme activity in drug metabolism. This alternative 13 pre-mRNA splicing may also contribute to the extensive variability in CYP2D6 activity observed 14 across individuals (41) . 15
Although the sample size in this study is substantial (N=1,497), the sample size of each brain 16 region is relatively small (mean = 115), so increasing sample size could help identify additional 17 brain functional SNPs and splicing junctions with increased confidence. Along the same lines, 18 quantifying feature differences between SCZ and normal controls samples would also be 19
informative. While we provide new targets implicated in SCZ, further understanding the 20 regulatory mechanisms of the genomic markers and gene structures identified here in animal or 21 cellular models (for example, human derived neurons) would be of great value . 22 In summary, we comprehensively analyzed expression features that are mediated by genomic 1 markers across the human brain regions, described the characteristics of these SNPs, and 2 demonstrated that the list of brain SNPs can be used to identify plausible candidate 3 transcripts/variants that are causally associated with SCZ. These findings will be of great use in 4
generating new animal and cellular models for SCZ. The association of SNX19 splicing junction Exon_8.10 has been previously characterized in our prior work (7) . Relative position of CYP2D6 SNPs and histone marker are indicated. (1), cortex derived primary cultured neurospheres (2), anterior caudate (3, 4) , cingulate gyrus (5, 6) , hippocampus middle (7, 8) , inferior temporal lobe (9, 10), 
